Semax vs Selank: What the Research Shows

Research use only. The information below summarizes preclinical scientific literature for laboratory and educational reference. It is not for human or veterinary use, and nothing here describes or suggests any form of administration. Pure Chems supplies these materials strictly as research chemicals.

Semax and Selank are two of the most frequently compared synthetic heptapeptides in the research literature. Both originated from work at the Russian Academy of Sciences, both are seven-amino-acid peptides built on a naturally occurring parent molecule, and both are studied in neuroscience models. Yet they descend from completely different parent peptides and are examined for distinct biological questions. This overview looks at how the two compounds are described side by side in preclinical studies, focusing on chemistry, reported mechanisms, and laboratory handling.

What are Semax and Selank

Semax is a synthetic heptapeptide analog of the adrenocorticotropic hormone fragment ACTH(4-10). Its sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The Pro-Gly-Pro tail was added to the biologically active ACTH fragment to slow enzymatic breakdown, and in the literature Semax is grouped with the nootropic and neuroprotective research peptides.

Selank is a synthetic heptapeptide analog of the endogenous immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg). Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, again with a Pro-Gly-Pro extension to increase stability. In the literature Selank is described mainly in the context of anxiolytic and immunoregulatory research rather than cognition.

So while the two peptides look like siblings on paper, their parent molecules place them in different research families: Semax sits alongside cognition and neuroprotection studies, and Selank sits alongside anxiety and immune-signaling studies.

Where they sit in the research literature

Both peptides have been examined primarily in rodent models and in vitro systems. A recurring theme in the comparative literature is that each peptide has been linked to changes in brain-derived neurotrophic factor (BDNF), but they are studied for different downstream questions.

Reported preclinical research areas for Semax

• Modulation of the BDNF and TrkB receptor system in the rodent hippocampus, examined in learning and memory paradigms.
• Neuroprotective activity in animal models of cerebral ischemia and oxidative stress.
• Effects on the expression of neurotrophin genes (BDNF and NGF) across brain regions in rats.
• Interactions with the dopaminergic and serotonergic systems in behavioral test batteries.

Reported preclinical research areas for Selank

• Anxiolytic-like behavioral profiles in rodent models, studied without the sedation seen with some reference compounds.
• Modulation of GABAergic and monoaminergic signaling in animal studies.
• Regulation of BDNF content in the hippocampus and prefrontal cortex in memory-related paradigms.
• Immunomodulatory and interferon-related effects reflecting its tuftsin heritage.

Chemistry and notes at a glance

• Semax: heptapeptide, sequence Met-Glu-His-Phe-Pro-Gly-Pro, molecular weight approximately 813.9 g/mol; parent molecule ACTH(4-10); research family nootropic and neuroprotective peptides.
• Selank: heptapeptide, sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, molecular weight approximately 751.9 g/mol; parent molecule tuftsin; research family anxiolytic and immunomodulatory peptides.
• Shared design feature: both use a C-terminal Pro-Gly-Pro motif intended to reduce enzymatic degradation of the active core sequence.
• Form: both are typically supplied as a lyophilized (freeze-dried) white powder for laboratory reconstitution.

For researchers who are new to these two peptides, the most useful mental model is that they are structurally analogous but functionally divergent: same peptide-engineering strategy, different biological target space.

Why the research use only label matters

Neither Semax nor Selank is approved as a medicine in the European Union. Both were developed and are registered as pharmaceutical products only in Russia, and they hold no marketing authorization under the European Medicines Agency or in most other jurisdictions. In the EU they are handled as research chemicals under the REACH framework, not as medicinal products.

That distinction is the whole point of the research use only label. As soon as a research chemical is presented with a therapeutic claim or with any suggestion of human use, it can fall under EU medicines law (Directive 2001/83/EC). Describing only the published preclinical literature, in the third person, keeps the material correctly classified and keeps the discussion honest. Neither compound is currently listed on the World Anti-Doping Agency Prohibited List, but regulatory and sporting status can change, so researchers working in regulated environments should verify the current position independently.

Handling and storage for researchers

Semax and Selank are handled almost identically in the laboratory because both are lyophilized peptides. General practice reported for research peptides of this type includes:

• Store the sealed lyophilized powder cold, typically at -20 C, protected from light and moisture, for long-term stability.
• Allow a sealed vial to reach room temperature before opening to limit condensation on the powder.
• Reconstitute in the laboratory with an appropriate sterile solvent, then keep the working solution refrigerated and use it within a short window.
• Avoid repeated freeze-thaw cycles of reconstituted material, and label all vials clearly as research chemicals.

For a fuller walk-through of solvent choices, see the Pure Chems note on bacteriostatic water versus acetic acid for peptide reconstitution.

Frequently asked questions

Are Semax and Selank the same thing?

No. They are both synthetic heptapeptides that share a Pro-Gly-Pro stabilizing tail, but Semax is derived from the ACTH(4-10) fragment and is studied mainly in cognition and neuroprotection research, while Selank is derived from tuftsin and is studied mainly in anxiety and immune-signaling research.

What is the main difference researchers focus on?

The parent molecule. Semax carries the pharmacological research context of an ACTH fragment, and Selank carries the context of the immunomodulatory peptide tuftsin. This shapes which experimental models and pathways each peptide is examined in.

Are Semax or Selank approved for any medical use in the EU?

No. Neither peptide holds marketing authorization in the European Union. They are approved as pharmaceuticals only in Russia and are treated as research chemicals elsewhere. They are supplied strictly for laboratory research.

Is it legal to buy Semax and Selank for research in the EU?

In the EU these peptides are generally handled as research chemicals under the REACH framework rather than as medicines, and are supplied for laboratory and analytical use only, not for human or veterinary use. Individual national rules can differ, so researchers should confirm the requirements that apply to their own institution and country.

Which one is better?

The literature does not frame them as competitors. They are studied for different questions, so a comparison is about matching a peptide to a research model rather than ranking one above the other.

Key takeaways

• Semax and Selank are both synthetic heptapeptides with a shared Pro-Gly-Pro stabilizing design but different parent molecules.
• Semax (from ACTH 4-10) appears in cognition and neuroprotection research; Selank (from tuftsin) appears in anxiolytic and immunomodulatory research.
• Both have been linked to changes in BDNF in rodent brain regions, a common thread in the comparative literature.
• Neither is an approved medicine in the EU; both are handled as research chemicals for laboratory use only.
• Laboratory handling is similar for the two: cold storage of the lyophilized powder, careful reconstitution, and clear research-only labeling.

Explore the individual research overviews for each compound, including Semax: what the research shows and Selank: what the research shows, and see the wider nootropic and racetam research compounds overview for how these peptides fit the broader category. Research-grade Semax and Selank are available from Pure Chems for laboratory use.

References

References sourced via PubMed.

1. Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research. 2006;1117(1):54-60. https://doi.org/10.1016/j.brainres.2006.07.108 | https://pubmed.ncbi.nlm.nih.gov/16996037/
2. Kolik LG, Nadorova AV, Antipova TA, et al. Selank, peptide analogue of tuftsin, protects against ethanol-induced memory impairment by regulating BDNF content in the hippocampus and prefrontal cortex in rats. Bulletin of Experimental Biology and Medicine. 2019;167(5):641-644. https://doi.org/10.1007/s10517-019-04588-9 | https://pubmed.ncbi.nlm.nih.gov/31625062/

Disclaimer: This article is provided for research and educational purposes only. Semax and Selank are research chemicals intended strictly for in vitro and laboratory investigation. They are not for human or veterinary use, not dietary supplements, and not medicinal products. Nothing here is medical advice or a therapeutic claim.